Osamu Nureki
Oprichter bij MODALIS THERAPEUTICS CORPORATION
Vermogen: 994 999 $ op 31-05-2024
Actieve functies van Osamu Nureki
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| MODALIS THERAPEUTICS CORPORATION | Directeur/Bestuurslid | 01-01-2016 | - |
| Oprichter | 01-01-2016 | - | |
Curreio, Inc.
 Curreio, Inc. Pharmaceuticals: MajorHealth Technology Curreio, Inc. is a drug discovery startup company founded in August 2019 and based in Tokyo, Japan. The Japanese company specializes in cryo-EM structural analysis technology and has unique technologies and know-how in protein production and purification, grid preparation, and 3D structural analysis. Curreio is currently developing internal/collaborative drug discovery projects and drug discovery support services for pharmaceutical companies using their cryo-EM technologies. The company's goal is to expand the possibilities of drug discovery for challenging proteins and protein-supramolecular complexes through structural analysis. The CEO is Motoki Nakai. | Directeur/Bestuurslid | 01-11-2019 | - |
| University of Tokyo | Corporate Officer/Principal | 01-04-2008 | - |
Loopbaan van Osamu Nureki
Opleiding van Osamu Nureki
| University of Tokyo | Graduate Degree |
Statistieken
Internationaal
| Japan | 4 |
Operationeel
| Director/Board Member | 2 |
| Founder | 1 |
| Graduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MODALIS THERAPEUTICS CORPORATION | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Curreio, Inc.
Curreio, Inc. Pharmaceuticals: MajorHealth Technology Curreio, Inc. is a drug discovery startup company founded in August 2019 and based in Tokyo, Japan. The Japanese company specializes in cryo-EM structural analysis technology and has unique technologies and know-how in protein production and purification, grid preparation, and 3D structural analysis. Curreio is currently developing internal/collaborative drug discovery projects and drug discovery support services for pharmaceutical companies using their cryo-EM technologies. The company's goal is to expand the possibilities of drug discovery for challenging proteins and protein-supramolecular complexes through structural analysis. The CEO is Motoki Nakai. | Health Technology |
- Beurs
- Insiders
- Osamu Nureki
- Ervaring
